Topical gel shows promising Results for Treatment of Skin Toxicities due to cancer treatment in Phase 2a trial
A novel topical gel, HT-001, shows promise as a treatment for cutaneous side effects caused by epidermal growth factor receptor inhibitor (EGFRi) cancer therapy. According to a press release from Hoth Therapeutics detailing phase 2a interim data, these results mark a significant milestone for addressing an unmet need in cancer treatment. In th trial 100% of patients achieved the primary endpoint of skin toxicity improvement by week 6 and 66% of patients reported a reduction in skin pain and itching.
These results highlight HT-001's potential to set a new standard of care for cancer patients, offering a safe and effective solution to maintain cancer treatments while managing cutaneous side effects.
“These results are a significant milestone, underscoring HT-001's potential to transform patient care by mitigating debilitating skin toxicities while maintaining critical cancer treatments,” said Robb Knie, CEO of Hoth Therapeutics. “Our data highlight HT-001's strong safety profile and the potential for it to set a new standard of care in this underserved area.”
Exceptional Patient Outcomes:
Data from the open-label portion of the CLEER-001 trial demonstrated remarkable success:
- 100% of patients achieved the primary efficacy endpoint of an ARIGA score ≤1, showing significant skin toxicity improvement by the six-week mark.
- 66% of patients reported reduced pain and itching scores, further enhancing quality of life.
Crucially, all patients maintained their full EGFRi dosage , preserving the cancer treatment's full therapeutic effect-a notable improvement compared to past reports showing widespread dose reductions or treatment halts due to skin-related side effects.
A Groundbreaking Approach:
The trial uses the proprietary Acneiform Rash Investigator Global Assessment Scale (ARIGA), developed in collaboration with onco-dermatology experts. The innovative scale ensures precise measurement and assessment of skin toxicity improvements.
Robb Knie , CEO of Hoth Therapeutics, remarked, "These results are a significant milestone, underscoring HT-001's potential to transform patient care by mitigating debilitating skin toxicities while maintaining critical cancer treatments. Our data highlight HT-001's strong safety profile and the potential for it to set a new standard of care in this underserved area."
A Strong Safety Profile:
No treatment-related adverse effects have been reported, reaffirming HT-001's excellent tolerability.
Looking Ahead:
"These interim findings align with a recent case report of rapid resolution of EGFRi-induced skin conditions using HT-001," added Knie. "As the study progresses, we anticipate further validating these results and are excited about the potential impact HT-001 could have on patient outcomes."
Hoth Therapeutics is committed to advancing groundbreaking treatments and improving patient lives through innovative therapies like HT-001.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.